ALLR

Allarity Therapeutics, Inc. [ALLR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ALLR Stock Summary

Top 10 Correlated ETFs

ALLR

Top 10 Correlated Stocks

ALLR

In the News

ALLR Financial details

Company Rating
-
Market Cap
989.47K
Income
-12.8M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
5
Optionable
No
Shortable
Yes
Earnings
24 May 2024
P/E
-0.09
Forward P/E
-
PEG
0.01
P/S
-
P/B
-0.36
P/C
-
P/FCF
-0.22
Quick Ratio
0.19
Current Ratio
0.28
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-175.23
EPS next Y
-
EPS next Q
-
EPS this Y
-94.93%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-17.77%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-61.16%
-
-
-
-
SMA20
-50%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-100%
ROE
2181%
ROC
10.16%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-13%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.01-3088.0
52W High
-99.95%
52W Low
-30.15%
RSI
45
Rel Volume
0.49
Avg Volume
59.62K
Volume
29.02K
Perf Week
-2.31%
Perf Month
-9.29%
Perf Quarter
36.96%
Perf Half Y
30.56%
-
-
-
-
Beta
0.242
-
-
Volatility
0.03%, 0.12%
Prev Close
-1.62%
Price
1.397
Change
-3.66%

Something similar

Top by Market Cap
GOOG
VFINX
BRYN.DE
TSLA
3V64.DE
Top Correlated ETFs
PFIX
MATH
Top Correlated Stocks
NMTC
DUO
EVTL
TACT
EKT.DE
Similar Market Cap
BION.L
UVEL.L
IVSG
KAYS
TYNE

Company Profile

Healthcare Biotechnology
  • Volume Average 59.62K
  • Market Capitalization 989.47K
  • Employee 5
  • CEO Mr. Thomas H. Jensen
  • Headquarters Cambridge,MA,US
  • IPO Date 2021-12-21
  • Website https://www.allarity.com

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.